After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

Human DPP4 / DPPIV / CD26 Protein

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human CD26/DPP4 Protein Product Information
Synonym:DPP4, ADABP, ADCP2, CD26, DPPIV, TP103
Protein Construction:The native mature form of human DPPIV (NP_001926.2) extracellular domain (Asn 29-Pro 766) was expressed and purified.
Expressed Host:Human Cells
Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Human CD26/DPP4 Protein QC Testing
Purity:> 70 % as determined by SDS-PAGE
Bio-Activity:1. Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is > 2,500 pmoles/min/μg.
2. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (Cat: 40071-V31B) was 20 nM.
3. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (Cat: 40071-V05B) was 50 nM.
4. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (ECD, aa 1-1297) (Cat: 40069-V08B) was 33 nM.
5. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike-His (aa 1-760) (Cat: 40021-V08H) was 12 nM.
Endotoxin:< 1.0 EU per μg of the protein as determined by the LAL method
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Asn 29
Molecule Mass:The recombinant human DPPIV exists as the mature active form, and consists of 738 amino acids with a predicted molecular mass of 85.4 kDa. The apparent molecular mass of the glycosylated rhDPPIV is approximately 95 kDa in SDS-PAGE under reducing conditions.
Formulation:Lyophilized from sterile 100mM NaCl, 50mM Tris, pH 7.5
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Human CD26/DPP4 Protein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Other CD26/DPP4 Recombinant Protein Products
DPP4 / CD26 Background

Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.

Human DPP4 / CD26 References
  • Doupis J, et al. (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 25(7): 627-43.
  • Havre PA, et al. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 13: 1634-45.
  • De Chiara L, et al. (2009) Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers. 7(6): 311-6.
  • Matteucci E, et al. (2009) Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 16(23): 2943-51.
  • Product nameProduct name
    Size / Price
    Catalog: 10688-HNCH-10
    List Price:   (Save )
    Price:      [How to order]
    AvailabilityIn StockShipping instructions